Amy E. Schade

605 total citations
10 papers, 337 citations indexed

About

Amy E. Schade is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amy E. Schade has authored 10 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amy E. Schade's work include Cancer-related Molecular Pathways (4 papers), Ubiquitin and proteasome pathways (3 papers) and RNA modifications and cancer (2 papers). Amy E. Schade is often cited by papers focused on Cancer-related Molecular Pathways (4 papers), Ubiquitin and proteasome pathways (3 papers) and RNA modifications and cancer (2 papers). Amy E. Schade collaborates with scholars based in United States, Germany and Canada. Amy E. Schade's co-authors include James A. DeCaprio, Martin Fischer, Timothy B. Branigan, Gerd A. Müller, Hilary E. Nicholson, Matthew G. Oser, Alan D. D’Andrea, Larissa A. Sambel, Geoffrey I. Shapiro and Hunter D. Reavis and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Investigation and Cancer Research.

In The Last Decade

Amy E. Schade

9 papers receiving 334 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amy E. Schade United States	7	249	117	56	44	31	10	337
Leighton H. Daigh United States	7	158 0.6×	127 1.1×	63 1.1×	35 0.8×	68 2.2×	8	300
J. Scott Beeler United States	8	189 0.8×	172 1.5×	46 0.8×	39 0.9×	60 1.9×	14	347
Chiou-Nan Shiue Sweden	6	445 1.8×	122 1.0×	42 0.8×	76 1.7×	18 0.6×	6	509
Rozario Thomas United States	5	188 0.8×	67 0.6×	33 0.6×	56 1.3×	24 0.8×	6	300
Terry J. Shackleford United States	6	220 0.9×	114 1.0×	30 0.5×	64 1.5×	48 1.5×	11	320
Jinsong Liu United States	7	199 0.8×	127 1.1×	85 1.5×	105 2.4×	28 0.9×	16	386
Odelia Nahum United States	9	193 0.8×	88 0.8×	34 0.6×	34 0.8×	46 1.5×	13	352
Landon Wark Canada	10	206 0.8×	79 0.7×	34 0.6×	46 1.0×	33 1.1×	15	313
Jin Woo Park South Korea	11	357 1.4×	52 0.4×	29 0.5×	61 1.4×	26 0.8×	19	406
Shengqi Hou United States	8	230 0.9×	58 0.5×	22 0.4×	113 2.6×	36 1.2×	12	295

Countries citing papers authored by Amy E. Schade

Since Specialization

Citations

This map shows the geographic impact of Amy E. Schade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy E. Schade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy E. Schade more than expected).

Fields of papers citing papers by Amy E. Schade

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy E. Schade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy E. Schade. The network helps show where Amy E. Schade may publish in the future.

Co-authorship network of co-authors of Amy E. Schade

This figure shows the co-authorship network connecting the top 25 collaborators of Amy E. Schade. A scholar is included among the top collaborators of Amy E. Schade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy E. Schade. Amy E. Schade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Nardi, Francesca, Naiara Perurena, Amy E. Schade, et al.. (2023). Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer. Journal of Clinical Investigation. 133(16). 12 indexed citations

Schade, Amy E., Ryan Kuzmickas, Kaia Mattioli, et al.. (2023). Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC. PLoS Biology. 21(4). e3002038–e3002038. 15 indexed citations

Schade, Amy E., Naiara Perurena, Kaia Mattioli, et al.. (2023). Abstract P4-08-11: AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution. Cancer Research. 83(5_Supplement). P4–8.

Fischer, Martin, Amy E. Schade, Timothy B. Branigan, Gerd A. Müller, & James A. DeCaprio. (2022). Coordinating gene expression during the cell cycle. Trends in Biochemical Sciences. 47(12). 1009–1022. 129 indexed citations

Branigan, Timothy B., David Kozono, Amy E. Schade, et al.. (2021). MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity. Cell Reports. 34(9). 108808–108808. 27 indexed citations

Kim, Jong Wook, Christian Berrios, Mi‐Ju Kim, et al.. (2020). STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells. eLife. 9. 39 indexed citations

Schade, Amy E., Matthew G. Oser, Hilary E. Nicholson, & James A. DeCaprio. (2019). Cyclin D–CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB. Oncogene. 38(25). 4962–4976. 50 indexed citations

Schade, Amy E., Martin Fischer, & James A. DeCaprio. (2019). RB, p130 and p107 differentially repress G1/S and G2/M genes after p53 activation. Nucleic Acids Research. 47(21). 11197–11208. 60 indexed citations

Schade, Amy E., Martin Fischer, & James A. DeCaprio. (2019). Abstract 2538: p53 activation induces cell cycle arrest by promoting DREAM and RB repression of cell cycle genes. Cancer Research. 79(13_Supplement). 2538–2538. 1 indexed citations

10.

Schade, Amy E., et al.. (2004). Creating a Comprehensive Training Documentation Program. Lab Animal. 33(4). 38–41. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact